A new, fast-acting mealtime insulin for adults living with Type 1 or Type 2 diabetes. Has been launch in the UK by Novo Nordisk. Fiasp (fast-acting insulin aspart, more commonly known as NovoRapid) more closely matches the natural physiological insulin response of a person without diabetes, after meals, compared with the current standard of care (rapid-acting insulin, NovoRapid [insulin aspart]). Fast-acting insulin aspart is being made available to the NHS at no additional cost versus conventional insulin aspart. And may help patients tighten the control of their blood sugar levels after meals.
Human trials have shown that fast-acting insulin aspart is absorb faster than insulin aspart. Appearing twice as fast in the bloodstream after injection. Which leads to improved control of blood sugar levels after meals. Fast-acting insulin aspart significantly improves overall control of blood sugar levels in patients. With Type 1 diabetes and had comparable control of blood sugar levels in patients with Type 2 diabetes. Versus insulin aspart. Control of blood sugar levels after meals was also significantly improved in patients with Type 1 or Type 2 diabetes at 1 hour after eating vs insulin aspart.
Diagram shows the evolution of mealtime insulins from Novo Nordisk.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.